Allena Pharmaceuticals (Allena Pharmaceuticals) Piotroski F-Score : 0 (As of May. 21, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Allena Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Allena Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

Allena Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Allena Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals Piotroski F-Score Chart

Allena Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Piotroski F-Score

Get a 7-Day Free Trial

N/A

2.00

Allena Pharmaceuticals Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Piotroski F-Score	Get a 7-Day Free Trial															1.00	2.00	2.00	2.00	2.00

How is the Piotroski F-Score calculated?

This Year (Jun22) TTM:

Last Year (Jun21) TTM:

Net Income was -12.692 + -10.363 + -11.813 + -8.435 = $-43.30 Mil.
Cash Flow from Operations was -11.477 + -12.803 + -20.037 + -4.557 = $-48.87 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jun21)
to the end of this year (Jun22) was
(30.285 + 43.87 + 34.757 + 21.732 + 17.811) / 5 = $29.691 Mil.
Total Assets at the begining of this year (Jun21) was $30.29 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $16.49 Mil.
Total Current Liabilities was $10.43 Mil.

Net Income was -8.026 + -10.258 + -11.636 + -13.972 = $-43.89 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jun20)
to the end of last year (Jun21) was
(29.108 + 31.968 + 38.931 + 40.474 + 30.285) / 5 = $34.1532 Mil.
Total Assets at the begining of last year (Jun20) was $29.11 Mil.
Long-Term Debt & Capital Lease Obligation was $10.22 Mil.
Total Current Assets was $28.32 Mil.
Total Current Liabilities was $7.80 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Allena Pharmaceuticals's current Net Income (TTM) was -43.30. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Allena Pharmaceuticals's current Cash Flow from Operations (TTM) was -48.87. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)	=	Net Income	/	Total Assets (Jun21)
	=	-43.303	/	30.285
	=	-1.42984976

ROA (Last Year)	=	Net Income	/	Total Assets (Jun20)
	=	-43.892	/	29.108
	=	-1.50790161

Allena Pharmaceuticals's return on assets of this year was -1.42984976. Allena Pharmaceuticals's return on assets of last year was -1.50790161. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Allena Pharmaceuticals's current Net Income (TTM) was -43.30. Allena Pharmaceuticals's current Cash Flow from Operations (TTM) was -48.87. ==> -48.87 <= -43.30 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun22)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Jun21 to Jun22
	=	0	/	29.691
	=	0

Gearing (Last Year: Jun21)	=	Long-Term Debt & Capital Lease Obligation	/	Average Total Assets from Jun20 to Jun21
	=	10.221	/	34.1532
	=	0.29926918

Allena Pharmaceuticals's gearing of this year was 0. Allena Pharmaceuticals's gearing of last year was 0.29926918. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun22)	=	Total Current Assets	/	Total Current Liabilities
	=	16.486	/	10.425
	=	1.58139089

Current Ratio (Last Year: Jun21)	=	Total Current Assets	/	Total Current Liabilities
	=	28.321	/	7.797
	=	3.63229447

Allena Pharmaceuticals's current ratio of this year was 1.58139089. Allena Pharmaceuticals's current ratio of last year was 3.63229447. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Allena Pharmaceuticals's number of shares in issue this year was 100.624. Allena Pharmaceuticals's number of shares in issue last year was 57.932. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

Gross Margin (Last Year: TTM)	=	Gross Profit	/	Revenue
	=	0	/	0
	=

Allena Pharmaceuticals's gross margin of this year was . Allena Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)	=	Revenue	/	Total Assets at the Beginning of This Year (Jun21)
	=	0	/	30.285
	=	0

Asset Turnover (Last Year)	=	Revenue	/	Total Assets at the Beginning of Last Year (Jun20)
	=	0	/	29.108
	=	0

Allena Pharmaceuticals's asset turnover of this year was 0. Allena Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score

Que. 1

Que. 2

Que. 3

Que. 4

Que. 5

Que. 6

Que. 7

Que. 8

Que. 9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Allena Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Allena Pharmaceuticals (OTCPK:ALNAQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.

Allena Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Piotroski F-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Newton Executive Park, Suite 202, Newton, MA, USA, 02462

Website

https://www.allenapharma.com

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Executives

Louis Md Brenner	officer: See Remarks	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick	director	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz	officer: Chief Financial Officer	4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan	officer: Chief Financial Officer	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller	director	C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p.	10 percent owner	C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp	10 percent owner	11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper	director, 10 percent owner	550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper	director, 10 percent owner	201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin	director, officer: Chief Executive Officer	C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139